Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 16/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901040 | 0.90 | CAPN1 (0.48) | CAPN1TACR3 | |
| SCHEMBL9901659 | 0.88 | CAPN1 (0.59) | CAPN1KCNA5TACR3 | |
| SCHEMBL9901543 | 0.88 | CAPN1 (0.46) | CAPN1KCNA5IL1BP2RX7 | |
| SCHEMBL9901064 | 0.85 | CAPN1 (0.48) | CAPN1TACR3 | |
| SCHEMBL9900940 | 0.85 | CAPN1 (0.63) | CAPN1 | |
| SCHEMBL1990406 | 0.82 | CAPN1 (0.65) | CAPN1 | |
| SCHEMBL9901539 | 0.81 | CAPN1 (0.52) | CAPN1 | |
| SCHEMBL9900663 | 0.80 | CAPN1 (0.57) | CAPN1KCNA5 | |
| SCHEMBL9901105 | 0.79 | CAPN1 (0.47) | CAPN1TACR3 | |
| SCHEMBL9900890 | 0.78 | CAPN1 (0.58) | CAPN1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062027-B2 | Carboxamide compounds and their use as calpain inhibitors V | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-23 | — | — | US | claimed |
| US-20140005227-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-02 | — | — | US | claimed |
| EP-2648731-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | ABBVIE DEUTSCHLAND (DE) | 2017-01-25 | — | — | EP | disclosed |
| US-9062027-B2 | Carboxamide compounds and their use as calpain inhibitors V | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-23 | — | — | US | disclosed |
| US-20140005227-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-02 | — | — | US | disclosed |
| EP-2648731-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | Abbvie Deutschland GmbH & Co. KG (DE) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012076639-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | ABBOTT GMBH & CO. KG (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005227-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | CAPN2, CAPN1, CAPN9 | CAPN1 2/4885KCNA5 1097/4885TACR3 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.